Transplantation of allogenic bone marrow in chronic myeloid leukemias


Cite item

Full Text

Abstract

Aim. To assess the role of allogenic bone marrow (ABM) transplantation in chronic myeloid leukemia (CML).
Material and methods. 44 ABM transplantations were performed in 37 CML patients in the chronic phase and 7 patients in acceleration or blast crisis.
Results. A complete molecular remission was achieved in 26 (59%) patients: 67.6% after ABM transplantation in the chronic phase and only 14.3% after myelotransplantation in non-chronic phase. Follow-up was 8-150 months (median - 59 months). Early lethality after ABM transplantation in the chronic phase was under 14%. A phase of the disease plays a key role in ABM transplantation. If it is made in a chronic phase, CML recurrence rate is low (in our series it was 14%), efficacy of donor's bone marrow lymphocyte transfusions is high. The second complete molecular remission was achieved in 3 of 4 cases of posttransplantation recurrences. Probability of maintenance of a complete remission after ABM transplantation in a chronic phase was 75%, recurrence-free survival - 64%), uneventful survival 55% for 90 months.
Conclusion. The experience of many years demonstrates high efficacy of ABM transplantation in the treatment of chronic myeloid leukemia. It promotes long-term molecular remission the maintenance of which did not require therapy in 65% patients.

References

  1. The Italian Cooperative Study Group on Chronic Myeloid Leukemia and Italian Group for Bone Marrow Transplantation. Monitoring treatment and survival in chronic myeloid leukemia. J. Clin. Oncol. 1999; 17: 1858-1868.
  2. Hehlmann R. Current CML therapy: progress and dilemma. Leukemia 2003; 17: 1010-1012.
  3. Druker B. J., Talpaz M., Resta D. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 2001; 344: 1031-1037.
  4. Merx K., Muller M. C., Kreil S. et al. Early reduction of BCR/ ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia 2002; 16: 1579-1583.
  5. Gratwohl A., Brand R., Apperley J. et al. Graft-vesus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. Blood 2002; 100 (12): 3877-3886.
  6. Любимова Л. С., Савченко В. Г., Менделеева Л. П. и др. Эффективность трансплантации аллогенного костного мозга у больных острыми лейкозами в фазе полной ремиссии и у больных хроническим миелолейкозами в хронической фазе. Тер. арх. 1999; 7: 27-32.
  7. Савченко В. Г. Новые стратегии в трансплантации стволовых гемопоэтических клеток. In: Abstracts of Russian-Norwegian conference in hematology. Saint-Petersburg; 2003. 10- 11.
  8. Goldman J. M., Druker B. D. Chronic myeloid leukemia: Current treatment options. Blood 2001; 98: 2039-2042.
  9. Dazzi F., Szydlo R. M., Craddock С. et al. Comparison of single dose and escalating dose regimens of donor lymphocyte infusion for relapser after allografting for chronic myeloid leukemia. Blood 2000; 95: 67-71.
  10. Choudhury A., Gajewski J. L., Liang L. С. et al. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1997; 89: 1133-1142.
  11. Weisdorf D. J., Anasetti C., Antin J. H. et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood 2002; 99 (6): 1971-1977.
  12. Виноградова О. А., Неверова А. Л., Савченко В. Г. и др. Мониторинг химеризма и минимальной остаточной болезни у больных хроническим миелолейкозом после аллогенной трансплантации костного мозга. Тер. арх. 2000; 7: 26-34.
  13. Демидова И. А., Савченко В. Г. Динамика приживления костного мозга и лимфогемопоэтический химеризм у больных после аллогенной трансплантации костного мозга. Тер. арх. 1995; 8: 10-15.
  14. Зотиков Е. А., Порешина Л. П., Кутьина Р. М. и др. Иммунологическая и гематологическая реконституция при трансплантации костного мозга от близкого родственника. Клин. лаб. диагн. 1997; 1: 10-13.
  15. Шпакова А. П., Булычева Т. И., Любимова Л. С., Менделеева Л. П. Особенности реакции MLC в определении гистосовместимости донора и реципиента при трансплантации аллогенного костного мозга больным гемобластозами. Тер. арх. 2000; 11: 62-67.
  16. Gratwohl A., Hermans J., Goldman J. M. et al, Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet 1998; 352: 1087- 1092.
  17. Radich J. Подходы к трансплантации при ХМЛ. Соврем. онкол. 2003; экстравып.: 19-23.
  18. Mendeleeva L. P., Savchenko V. G., Lubimova L. S. et al. Donor lymphocyte infusion for leukemia relapse after allogeneic bone marrow transplantation. Hematol. J. 2001; 1 (suppl. 1): 216.
  19. Elmaagacli A. H, Basoglu S., Peceny R. et al. Improved disease-free-survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia. Blood 2002; 99 (4): 1130-1135.
  20. Thomas E. D. et al., Eds. Haemopoietic cell transplantation. 1998. 16.
  21. Kroger N., Zabelina Т., Kruger W. et al. In vivo T-cell depletion with pretransplant antitymocyte globulin reduced graftversus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors. Bone Marrows Transplant 2002' 29 (8): 683-689.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2004 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies